Phase 4 N=142 A Trial of Everolimis in Patients With Advanced Renal Cell Carcinoma.
Renal Cell Carcinoma
Primary: PFS (Progression-Free Survival) — 27.71 Weeks
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=226 Pre-surgical Detection of Clear Cell Renal Cell Carcinoma (ccRCC) Using Radiolabeled G250-Antibody
Renal Cell Carcinoma · Kidney Cancer
Primary: Sensitivity and Specificity of 124I-cG250 PET/CT Versus Diagnostic CT. — 0.76; 0.86; 0.86; 0.47 Proportion of participants — p=0.023
N/A N=1,349 Clinical Outcome Of Advanced Renal Cell Carcinoma In Taiwan
Renal Cell Carcinoma
Primary: Duration of Sunitinib and Pazopanib Treatment in Participants — 171; 114.5 days
Phase 2 N=10 Carfilzomib in Refractory Renal Cell Carcinoma (RCC)
Kidney Cancer
Primary: Progression Free Survival (PFS) of Carfilzomib Therapy in Participants With Refractory Or Intolerant to Prior Therapy — 1.8 Months
Phase 2 N=92 Study of IMO-2055 in Metastatic or Locally Recurrent Clear Cell Renal Carcinoma
Renal Cell Carcinoma
Primary: Best Response by RECIST v1.0 — 0; 1; 0; 1 Participants
Phase 2 N=4 MK-3795 (PT2385) for the Treatment of Von Hippel-Lindau Disease-Associated Clear Cell Renal Cell Carcinoma (MK-3795-003)
VHL Gene Mutation · VHL · VHL Syndrome
Primary: Overall Response Rate (ORR) in VHL Disease-Associated ccRCC Tumors — 0.0 Percentage of Participants
Phase 2 N=108 Phase II Study of Afinitor vs. Sutent in Patients With Metastatic Non-Clear Cell Renal Cell Carcinoma
Advanced Non-clear Cell Renal Cell Carcinoma
Primary: Anti-tumor Activity as Measured by Median Progression Free Survival Time — 5.6; 8.3 Months — p=0.157
Phase 2 N=65 Study of Atezolizumab + Bevacizumab in Patients With Advanced Non-Clear Cell Renal Cell Carcinoma
Advanced Non-Clear Cell Kidney Cancer
Primary: Best Overall Response Rate — 33 percentage of participants
Phase 2 N=168 BMS-936558 (MDX-1106) In Subjects With Advanced/Metastatic Clear-Cell Renal Cell Carcinoma (RCC)
Renal Cell Carcinoma
Primary: Progression Free Survival (PFS) — 2.63; 4.11; 4.17 Months
N/A N=14 Intraoperative Folate Targeted Fluorescence in Renal Cell Carcinoma
Renal Cell Carcinoma
Primary: Number of Participants With Presence of Fluorescence of cT1 RCC in Partial Nephrectomy Specimens — 10 Participants
Phase 2 N=74 A Phase II Study of GSK1363089 (Formerly XL880) for Papillary Renal-Cell Carcinoma (PRC)
Carcinoma, Renal Cell
Primary: Overall Response Rate (ORR) Per Response Evaluation Criteria in Solid Tumors (RECIST) Criteria Version 1.0 — 13.5; 13.5 Percentage of participants
Phase 2 N=50 Neoadjuvant Clinical Trial to Evaluate the Efficacy of Bevacizumab for Renal Cell Carcinoma
Renal Cell Carcinoma · Kidney Cancer
Primary: Progression Free Survival (PFS) — 11 months
Phase 1 N=25 Sunitinib for Metastatic Renal Cell Cancer With Imaging Biomarker Assessments for the Early Prediction of Tumor Response
Renal Cell Cancer
Primary: Metabolic Response — 5 participants
Phase 2 N=275 Study of Pembrolizumab (MK-3475) Monotherapy in Locally Advanced/Metastatic Renal Cell Carcinoma (MK-3475-427/KEYNOTE-427)
Renal Cell Carcinoma
Primary: Objective Response Rate (ORR) — 36.4; 26.7 Percentage of Participants
N/A N=34 Study of PSMA-targeted 18F-DCFPyL PET/CT in the Evaluation of Patients With Renal Cell Carcinoma
Renal Cell Carcinoma · Kidney Cancer
Primary: Number of Participants With 18F-DCFPyL PET/CT Detected Sites of Metastatic Renal Cell Carcinoma (RCC) — 34 Participants
Phase 2 N=57 Sunitinib Malate in Patients With Non-Clear Cell Renal Cell Cancer
Renal Cell Cancer · Kidney Cancer
Primary: Number of Participants With Response to Treatment — 0; 3; 29; 23 participants
Phase 2 N=20 A Phase 2 Study of the MET Kinase Inhibitor INC280 in Papillary Renal Cell Cancer
Kidney Cancer
Primary: Percentage of Participants With Response — 0; 15; 65; 10 percentage of participants
Phase 3 N=435 Safety and Efficacy of GW786034 (Pazopanib) In Metastatic Renal Cell Carcinoma
Carcinoma, Renal Cell
Primary: Progression-free Survival — 9.2; 4.2 months — p=.0000001
Phase 2 N=26 Bevacizumab and Aldesleukin in Treating Patients With Metastatic Clear Cell Carcinoma of the Kidney
Kidney Cancer
Primary: Progression Free Survival — 9.6 months
Phase 1 N=5 TIL Therapy for Metastatic Renal Cell Carcinoma
Metastatic Renal Cell Carcinoma
Primary: Number of Patients in Which the Treatment Was Tolerable — 5 Participants
Phase 2 N=21 Neoadjuvant Pazopanib in Renal Cell Carcinoma
Renal Cell Carcinoma
Primary: Response Rate — 8 Participants
Phase 2 N=96 MLN0128 and MLN0128 + MLN1117 Compared With Everolimus in the Treatment of Adults With Advanced or Metastatic Clear-Cell Renal Cell Carcinoma
Clear-cell Metastatic Renal Cell Carcinoma
Primary: Progression-Free Survival (PFS) — 3.8; 3.6; 3.1 months — p==0.388
Phase 2 N=225 GW786034 In Subjects With Locally Recurrent Or Metastatic Clear Cell Renal Cell Carcinoma
Carcinoma, Renal Cell
Primary: Overall Response by RECIST Criteria — 3; 75; 101; 24 participants
Phase 2 N=57 Everolimus and Bevacizumab in Advanced Non-Clear Cell Renal Cell Carcinoma (RCC)
Renal Cell Carcinoma
Primary: To Evaluate the Efficacy of Combining Everolimus and Bevacizumab in Patients With Advanced RCC of Non-clear Cell Histology — 78 percent of participants
Phase 2 N=20 Neoadjuvant Sitravatinib in Combination With Nivolumab in Patients With Clear Cell Renal Cell Carcinoma
Clear Cell Renal Cell Carcinoma
Primary: Percentage of Participants Who Achieved a Point in Time Objective Response (Either Complete or Partial Response [CR or PR]) Prior to Surgery — 2; 0 Participants
Phase 2 N=25 SBRT (Stereotactic Body Radiation Therapy) in Combination With Nivolumab/Ipilimumab in Renal Cell Carcinoma (RCC) / Kidney Cancer Patients
Kidney Cancer Metastatic · Kidney Cancer · Kidney Cancer, Stage IV
Primary: Number of Participants With Treatment-related Adverse Events Grade 3 or Higher as Assessed by CTCAE v4.0 — 9 Participants
Phase 2 N=69 Pazopanib Versus Temsirolimus in Poor-Risk Clear-Cell Renal Cell Carcinoma (RCC)
Kidney Cancer
Primary: Progression Free Survival (PFS) — 2.7; 5.2 months
Phase 2 N=20 LBH589 Treatment for Refractory Clear Cell Renal Carcinoma
Renal Cell Carcinoma
Primary: Progression-free Survival — 1.7 months
Phase 2 N=80 Bevacizumab (Avastin) and RAD001(Everolimus)in the Treatment of Advanced Clear Cell Renal Carcinoma
Kidney Cancer
Primary: Progression Free Survival (PFS), the Length of Time, in Months, That Patients Were Alive From Their First Date of Protocol Treatment Until Worsening of Their Disease…
Phase 2 N=134 Everolimus as Second-line Therapy in Metastatic Renal Cell Carcinoma
Metastatic Renal Cell Carcinoma
Primary: Progression-free Survival (PFS) - All Participants — 7.4 months